Autopsy report · NCT06068543
Reducing Frailty for Older Cancer Survivors Using Supplements II
Cause of deathRegulatory or ethics
“The study has been suspended by the IRB pending review of a study-related issue”
Life of this trial
- Registered 1 year 1 month before it started.
- Suspended: paused, and may or may not restart.
- 118 participants planned (an estimate, not an actual count).
Vital statistics
- Status
- Suspended
- Phase
- Phase 2
- Sponsor
- University of Rochester
- Sponsor type
- University, hospital or other
- Conditions
- Frailty; Inflammation
- Interventions
- Epigallocatechin-3-Gallate (EGCG); Microcrystalline cellulose (MCC); Ascorbic Acid (Vitamin C)
- Participants
- 118 (planned, not actual)
- Sites
- 1
- Countries
- United States
Trials that died the same way
- A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults
“The study was suspended by the IRB of record and subsequently terminated” - Exhaled Breath Condensate pH in Patients With Cough Caused by Gastroesophageal Reflux
“IRB approval not renewed/approval lapsed. Prior status: insufficient enrollment; study suspended pending analysis” - Simvastatin Nasal Rinses for the Treatment of COVID-19 Mediated Dysomsia
“Study halted prematurely; IRB approval not obtained” - The Effect of Movement Education on Jumping/Landing Quality in High School Athletes
“Study was updated and is now under IRB #2023-0499” - Antibiotics and Tissue Expanders in Breast Reconstruction
“The study was withdrawn prior to IRB approval.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.